地塞米松缓释微粒控制儿童白内障术后炎症临床观察  

Dexamethason slow-released granules on inflammation control in children performed with intraocular lens implantation for cataract

作　　者：毕毅敏[1] 李超[1] 余涵[1] 

机构地区：[1]新乡医学院第三附属医院眼科,河南新乡453003

出　　处：《新乡医学院学报》2005年第5期504-505,共2页Journal of Xinxiang Medical University

摘　　要：目的观察地塞米松缓释微粒植入前房内对控制儿童超声乳化白内障人工晶体植入术后炎症的疗效。方法对68例白内障患儿行小切口超声乳化人工晶体植入术,其中34例植入地塞米松缓释微粒,另34例为对照组,观察术后1d3、d、7d房水混浊及纤维蛋白渗出及纤维膜形成情况。结果植入地塞米松缓释微粒组房水混浊程度及纤维蛋白渗出及膜形成情况明显轻于对照组(P<0.05)。使用过程中未见与药物有关的不良反应。结论地塞米松缓释微粒植入前房用于儿童白内障控制术后炎症安全、有效、可靠。Objective To observe effects of Dexamethason（DXM） slow-released granules placed into anterior chamber on inflammation control after intraocular lens（IOL） implantantion for children cataract. Methods Sixty-eight children with cataract were performed with phacoemulsification cataract extraction and IOL implantation. Thirty-four cases were administered with DXM slow-released granules placed into anterior chamber at the same time, the other 34 cases ms control.. Acqueous opacity, fibroprotein exudates and membrane formation were observed at 1,3 and 7 day postoperatively. Results Inflammation including acqueous opacity, fibroprotein exudates and membrane formation was significantly milder in the treatment group than that in the control group（P 〈 0.05）. No complications related to medication occurred. Conclusion Placement of DXM slow-released granules in anterior chamber is a safe and effective method to control inflammation after IOL implantation for children cataract.

关 键 词：地塞米松 缓释微粒 儿童白内障 

分 类 号：R779.7[医药卫生—眼科]